PharmEasy plans to procure $300 million at reduced valuation; potential first major Indian down round

  • PharmEasy plans to raise $300 million in funding at a 90% markdown, reducing its valuation by half.
  • Healthcare group Manipal might lead this round; the start-up aims to repay its loan from Goldman Sachs.
  • If successful, this new round will bring PharmEasy’s valuation down to $500 million-$600 million, marking the first major down round for an Indian unicorn.
Join 2 million subscribers

A curated newsletter that summarizes the important news at the intersection of Global tech, India Tech and AI.

Delivered 8 AM. Daily.
nextbigwhat We would like to show you notifications for the latest news and updates.
Allow Notifications